Spebrutinib

Spebrutinib (LMK-435) is an oral, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK) . It is utilized in preclinical research for studying B-cell malignancies and autoimmune diseases, demonstrating activity in both cellular assays and animal models.

Product Specifications

CAS Number

1202757-89-8

Product Name Alternative

Yes, Spebrutinib, AVL 292, AVL292, AVL-292, Bruton tyrosine kinase, Btk, BTK, CC292, CC-292, CC 292, BRK, c-Src, inhibit, LMK 435, LMK435, LMK-435, Lyn, Inhibitor

Field of Research

Cardiovascular Research, Signal Transduction

Purity

97.02% (May vary between batches)

Solubility

H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.72 mM) ; DMSO:79 mg/mL (186.57 mM)